Healthy Aging Resources to Thrive (HART)
Launched by KAISER PERMANENTE · Nov 12, 2018
Trial Information
Current as of September 16, 2025
Completed
Keywords
ClinConnect Summary
Healthy Aging Resources to Thrive (HART) is a two-stage randomized controlled trial (RCT) of adults over age 60 with obesity to determine the efficacy of a novel sitting-reduction intervention and its impact on cardiometabolic risk markers. Participants will be randomized to a 6-month sitting reduction intervention (termed I-STAND) or healthy-living attention control (Stage 1). All participants will be mailed a scale and a blood pressure monitor (to keep) which will be used during the phone-based measurement visits at Baseline, 3, 6 and 12 months. All participants will have phone-based Coac...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: • Self-reported sitting time of 6+ hours per day
- • BMI ≥30 and \<50 kg/m2
- • men and women of all races and ethnicities from anywhere in the KPWA region (state-wide)
- • We will oversample people of color statewide
- • Able to walk one block
- • Able to speak and read English,
- • no self-reported vision limitations, sedentary time, use of an assistive device, able to stand.
- • no cognitive impairment that is perceived by the study staff during phone screening
- • Willingness to wear device (activPAL)
- • Willingness to participate in study for a full year
- • Continuously enrolled at KP for previous 12 months
- • Not on the No Contact list
- • Not previously enrolled in ISTAND or TABS
- • Not currently enrolled in ACT, STOP-FALLS or SMARRT studies
- Exclusion Criteria:
- • unable to speak and read English (phone screen)
- • unable to walk 1 block (with or without assistive devices) (phone screen)
- • self-reported sitting time less than 6 hours per day (phone screen)
- • diagnosis codes indicating hearing loss, dementia or serious mental illness (e.g., schizophrenia, bipolar disorder), or a terminal or serious illness (e.g., cancer) in the past 2 years (from the EMR)
About Kaiser Permanente
Kaiser Permanente is a leading integrated health care organization that combines a health plan with a network of hospitals and physicians to provide comprehensive medical services. With a strong commitment to advancing medical research and improving patient care, Kaiser Permanente sponsors clinical trials across various therapeutic areas. The organization emphasizes innovative approaches to health care, leveraging its extensive data and resources to support evidence-based treatments and enhance patient outcomes. Through its rigorous research initiatives, Kaiser Permanente aims to contribute to the advancement of medical knowledge and the development of new therapies that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Dori E Rosenberg, PhD, MPH
Principal Investigator
Kaiser Permanente
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials